Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9BVS4
UPID:
RIOK2_HUMAN
Alternative names:
RIO kinase 2
Alternative UPACC:
Q9BVS4; D6RDI3; Q9NUT0
Background:
Serine/threonine-protein kinase RIO2, also known as RIO kinase 2, plays a pivotal role in the cytoplasmic maturation of the 40S ribosomal subunit. It facilitates the export of 40S pre-ribosome particles from the nucleus to the cytoplasm, with its kinase activity being crucial for the release of specific proteins from the late pre-40S and the processing of 18S-E pre-rRNA to mature 18S rRNA. Additionally, RIO2 regulates the timing of the metaphase-anaphase transition during mitotic progression, a process influenced by phosphorylation, likely by PLK1.
Therapeutic significance:
Understanding the role of Serine/threonine-protein kinase RIO2 could open doors to potential therapeutic strategies.